A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

NCT04553978 | Unknown Phase 1 FDA Drug

• 1 other identifier: WD-1603-1004
• Study Type: interventional
• Target: 8
• Locations: 0 countries
• Sites: N/A

Brief Summary

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (2)

• Cmax

  Blood samples will be collected at designed timepoints pre and post dose

  Day 1 and Day 2

• AUC

  Blood samples will be collected at designed timepoints pre and post dose

  Day 1 and Day 2

Study Arms (2)

Treatment A

EXPERIMENTAL

After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel. Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary.

Drug: WD-1603

Treatment B

EXPERIMENTAL

At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel. Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary.

Drug: WD-1603

Interventions

WD-1603 DRUG

WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Treatment A; Treatment B

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).
• Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as weight in kg / height in m2, a minimum body weight of 50.0 kg.
• Not having any significant disease or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (P/A view) recordings.
• Able to understand and comply with the study procedures, in the opinion of the principal investigator.
• Able to give voluntary written informed consent for participation in the trial.
• In case of female subjects:
• Surgically sterilized at least 6 months prior to study participation
• If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
• And
• Serum Pregnancy test must be negative.
• Female must also be willing to abstain from ovum donation from check-in of period-I and for at least 28 days after the last study drug administration.
• Female subjects of non-childbearing potential must be either post-menopausal (post-menopausal is defined as being amenorrheic for at least 1 year without another cause and a follicle-stimulating hormone \[FSH\] level ≥26 IU/L) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation).
• Male subjects with female sexual partners of childbearing potential must be willing to use and willing to continue using medically acceptable contraception (true abstinence, vasectomy, or male condom for subjects plus an additional method of contraception for their female partners) from check-in of period-I until 28 days following the last administration of study drug.
• Men must also be willing to abstain from sperm donation from check-in of period-I and for at least 28 days after the last study drug administration.
• Subjects should be literate.

You may not qualify if:

• Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of the excipients or any related drug.
• History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, cardiovascular, immunological, dermatological, gastrointestinal system, and central nervous system with dyskinesia, depression, suicidal thought, or any other body system.
• History or presence of ophthalmic diseases such as wide angle glaucoma and ocular hypertension.
• Ingestion of a medicine (prescribed \& over the counter (OTC) medication including herbal remedies and MAO inhibitors) at any time within 30 days before check-in in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.
• Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
• Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
• A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to check-in of Period I.
• Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
• The presence of clinically significant abnormal laboratory values during screening.
• History or presence of psychiatric disorders.
• A history of difficulty in donating blood.
• Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
• Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication\*\*.
• \*\* If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
• A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.

Sponsors & Collaborators

• Hong Kong WD Pharmaceutical Co., Limited: lead

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 13, 2020
• First Posted: September 18, 2020
• Study Start: September 18, 2020
• Primary Completion: March 18, 2021
• Study Completion: March 18, 2021
• Last Updated: September 22, 2020

Record last verified: 2020-09